Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.

Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Soh J, Fujiwara T, Toyooka S.

Cancer Sci. 2019 Jun 4. doi: 10.1111/cas.14089. [Epub ahead of print]

2.

Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.

Chen Y, Sumardika IW, Tomonobu N, Kinoshita R, Inoue Y, Iioka H, Mitsui Y, Saito K, Ruma IMW, Sato H, Yamauchi A, Murata H, Yamamoto KI, Tomida S, Shien K, Yamamoto H, Soh J, Futami J, Kubo M, Putranto EW, Murakami T, Liu M, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Neoplasia. 2019 May 14;21(7):627-640. doi: 10.1016/j.neo.2019.04.006. [Epub ahead of print]

3.

Red-shifting mutation of light-driven sodium-pump rhodopsin.

Inoue K, Del Carmen Marín M, Tomida S, Nakamura R, Nakajima Y, Olivucci M, Kandori H.

Nat Commun. 2019 Apr 30;10(1):1993. doi: 10.1038/s41467-019-10000-x.

4.

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.

Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.

Anticancer Res. 2019 Apr;39(4):1767-1775. doi: 10.21873/anticanres.13283.

PMID:
30952716
5.

Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.

Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S.

Int J Oncol. 2019 Jun;54(6):2139-2148. doi: 10.3892/ijo.2019.4768. Epub 2019 Apr 1.

PMID:
30942424
6.

Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.

Chen Y, Sumardika IW, Tomonobu N, Winarsa Ruma IM, Kinoshita R, Kondo E, Inoue Y, Sato H, Yamauchi A, Murata H, Yamamoto KI, Tomida S, Shien K, Yamamoto H, Soh J, Liu M, Futami J, Sasai K, Katayama H, Kubo M, Putranto EW, Hibino T, Sun B, Nishibori M, Toyooka S, Sakaguchi M.

Cancer Lett. 2019 Jun 28;452:178-190. doi: 10.1016/j.canlet.2019.03.023. Epub 2019 Mar 21.

7.

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations.

Ogoshi Y, Shien K, Yoshioka T, Torigoe H, Sato H, Sakaguchi M, Tomida S, Namba K, Kurihara E, Takahashi Y, Suzawa K, Yamamoto H, Soh J, Toyooka S.

Oncol Lett. 2019 Mar;17(3):2729-2736. doi: 10.3892/ol.2019.9908. Epub 2019 Jan 8.

8.

Regulation of animal behavior by epigenetic regulators.

Shimaji K, Tomida S, Yamaguchi M.

Front Biosci (Landmark Ed). 2019 Mar 1;24:1071-1084.

PMID:
30844731
9.

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.

Namba K, Tomida S, Matsubara T, Takahashi Y, Kurihara E, Ogoshi Y, Yoshioka T, Takeda T, Torigoe H, Sato H, Shien K, Yamamoto H, Soh J, Tsukuda K, Toyooka S.

BMC Cancer. 2019 Feb 26;19(1):175. doi: 10.1186/s12885-019-5374-1.

10.

Proposal of new combination, Cutibacterium acnes subsp. elongatum comb. nov., and emended descriptions of the genus Cutibacterium, Cutibacterium acnes subsp. acnes and Cutibacterium acnes subsp. defendens.

Dekio I, McDowell A, Sakamoto M, Tomida S, Ohkuma M.

Int J Syst Evol Microbiol. 2019 Apr;69(4):1087-1092. doi: 10.1099/ijsem.0.003274. Epub 2019 Feb 14.

PMID:
30762517
11.

Neuroplastin-β mediates S100A8/A9-induced lung cancer disseminative progression.

Sumardika IW, Chen Y, Tomonobu N, Kinoshita R, Ruma IMW, Sato H, Kondo E, Inoue Y, Yamauchi A, Murata H, Yamamoto KI, Tomida S, Shien K, Yamamoto H, Soh J, Futami J, Putranto EW, Hibino T, Nishibori M, Toyooka S, Sakaguchi M.

Mol Carcinog. 2019 Jun;58(6):980-995. doi: 10.1002/mc.22987. Epub 2019 Feb 27.

PMID:
30720226
12.

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, Soh J, Tomida S, Toyooka S.

Mol Cancer Res. 2019 Feb;17(2):499-507. doi: 10.1158/1541-7786.MCR-18-0628. Epub 2018 Nov 21.

PMID:
30463991
13.

Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jul 15;145(2):569-575. doi: 10.1002/ijc.31982. Epub 2018 Dec 14.

PMID:
30414170
14.

exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jun 15;144(12):3138-3145. doi: 10.1002/ijc.31945. Epub 2018 Dec 4.

PMID:
30365872
15.

Transduced caudal-type homeobox (CDX) 2/CDX1 can induce growth inhibition on CDX-deficient gastric cancer by rapid intestinal differentiation.

Nakayama C, Yamamichi N, Tomida S, Takahashi Y, Kageyama-Yahara N, Sakurai K, Takeuchi C, Inada KI, Shiogama K, Nagae G, Ono S, Tsuji Y, Niimi K, Fujishiro M, Aburatani H, Tsutsumi Y, Koike K.

Cancer Sci. 2018 Dec;109(12):3853-3864. doi: 10.1111/cas.13821. Epub 2018 Oct 26.

16.

[A Case of Bone Marrow Carcinomatosis of Occult Breast Cancer Treated Effectively with Fulvestrant].

Tomida S, Nakatsukasa K, Taguchi T.

Gan To Kagaku Ryoho. 2018 Sep;45(9):1381-1384. Japanese.

PMID:
30237387
17.

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.

Takahashi Y, Shien K, Tomida S, Oda S, Matsubara T, Sato H, Suzawa K, Kurihara E, Ogoshi Y, Namba K, Yoshioka T, Torigoe H, Yamamoto H, Soh J, Toyooka S.

Cancer Sci. 2018 Nov;109(11):3634-3642. doi: 10.1111/cas.13797. Epub 2018 Oct 6.

18.

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.

Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.

Cancer Sci. 2018 Oct;109(10):3183-3196. doi: 10.1111/cas.13763. Epub 2018 Sep 14.

19.

Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer.

Watanabe M, Kagawa S, Kuwada K, Hashimoto Y, Shigeyasu K, Ishida M, Sakamoto S, Ito A, Kikuchi S, Kuroda S, Kishimoto H, Tomida S, Yoshida R, Tazawa H, Urata Y, Fujiwara T.

Cancer Sci. 2018 Oct;109(10):3263-3271. doi: 10.1111/cas.13760. Epub 2018 Sep 23.

20.

Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.

Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.

Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11.

21.

Identification of marker genes and pathways specific to precancerous duodenal adenomas and early stage adenocarcinomas.

Sakaguchi Y, Yamamichi N, Tomida S, Takeuchi C, Kageyama-Yahara N, Takahashi Y, Shiogama K, Inada KI, Ichinose M, Fujishiro M, Koike K.

J Gastroenterol. 2019 Feb;54(2):131-140. doi: 10.1007/s00535-018-1489-4. Epub 2018 Jun 28.

PMID:
29951927
22.

A distinct abundant group of microbial rhodopsins discovered using functional metagenomics.

Pushkarev A, Inoue K, Larom S, Flores-Uribe J, Singh M, Konno M, Tomida S, Ito S, Nakamura R, Tsunoda SP, Philosof A, Sharon I, Yutin N, Koonin EV, Kandori H, Béjà O.

Nature. 2018 Jun;558(7711):595-599. doi: 10.1038/s41586-018-0225-9. Epub 2018 Jun 20.

PMID:
29925949
23.

Hydrogen-bonding network at the cytoplasmic region of a light-driven sodium pump rhodopsin KR2.

Tomida S, Ito S, Inoue K, Kandori H.

Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):684-691. doi: 10.1016/j.bbabio.2018.05.017. Epub 2018 May 28.

PMID:
29852143
24.

[Clinical Implementation of Precision Medicine].

Tomida S, Toyooka S.

Gan To Kagaku Ryoho. 2018 Apr;45(4):601-604. Japanese.

PMID:
29650812
25.

Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.

Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.

Carcinogenesis. 2018 May 3;39(5):719-727. doi: 10.1093/carcin/bgy044.

PMID:
29546323
26.

Long-distance perturbation on Schiff base-counterion interactions by His30 and the extracellular Na+-binding site in Krokinobacter rhodopsin 2.

Shigeta A, Ito S, Kaneko R, Tomida S, Inoue K, Kandori H, Kawamura I.

Phys Chem Chem Phys. 2018 Mar 28;20(13):8450-8455. doi: 10.1039/c8cp00626a.

PMID:
29537054
27.

Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.

Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.

Cancer Sci. 2018 May;109(5):1493-1502. doi: 10.1111/cas.13571. Epub 2018 Apr 15.

28.

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Asano H, Soh J, Tsukuda K, Nagasaka T, Fujiwara T, Toyooka S.

Cancer Sci. 2018 Apr;109(4):1166-1176. doi: 10.1111/cas.13546. Epub 2018 Mar 25.

29.

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.

Ninomiya K, Ohashi K, Makimoto G, Tomida S, Higo H, Kayatani H, Ninomiya T, Kubo T, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K.

Sci Rep. 2018 Jan 31;8(1):1955. doi: 10.1038/s41598-018-20326-z.

30.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

31.

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.

Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H.

Oncogene. 2018 Mar;37(13):1775-1787. doi: 10.1038/s41388-017-0035-9. Epub 2018 Jan 19.

PMID:
29348459
32.

CCL28-Deficient Mice Have Reduced IgA Antibody-Secreting Cells and an Altered Microbiota in the Colon.

Matsuo K, Nagakubo D, Yamamoto S, Shigeta A, Tomida S, Fujita M, Hirata T, Tsunoda I, Nakayama T, Yoshie O.

J Immunol. 2018 Jan 15;200(2):800-809. doi: 10.4049/jimmunol.1700037. Epub 2017 Dec 13.

33.

Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer.

Torigoe H, Soh J, Tomida S, Namba K, Sato H, Katsui K, Hotta K, Shien K, Yamamoto H, Yamane M, Kanazawa S, Kiura K, Miyoshi S, Toyooka S.

J Thorac Dis. 2017 Sep;9(9):3076-3086. doi: 10.21037/jtd.2017.08.87.

34.

Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.

Yamamoto H, Toyooka S, Ninomiya T, Matsumoto S, Kanai M, Tomida S, Kiura K, Muto M, Suzawa K, Desmeules P, Kris MG, Li BT, Ladanyi M.

Oncologist. 2018 Feb;23(2):150-154. doi: 10.1634/theoncologist.2017-0345. Epub 2017 Nov 16.

35.

Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.

Chen H, Shien K, Suzawa K, Tsukuda K, Tomida S, Sato H, Torigoe H, Watanabe M, Namba K, Yamamoto H, Soh J, Asano H, Miyoshi S, Toyooka S.

Oncol Lett. 2017 Oct;14(4):4349-4354. doi: 10.3892/ol.2017.6678. Epub 2017 Jul 26.

36.

β-1,3-Galactosyl-O-Glycosyl-Glycoprotein β-1,6-N-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility.

Sumardika IW, Youyi C, Kondo E, Inoue Y, Ruma IMW, Murata H, Kinoshita R, Yamamoto KI, Tomida S, Shien K, Sato H, Yamauchi A, Futami J, Putranto EW, Hibino T, Toyooka S, Nishibori M, Sakaguchi M.

Oncol Res. 2018 Apr 10;26(3):431-444. doi: 10.3727/096504017X15031557924123. Epub 2017 Sep 18.

PMID:
28923134
37.

Effects of Cold Ischemia on RNA Stability and Quality of Lung Tissues Based on Standard PREanalytical Code Categorization.

Matsubara T, Tomida S, Soh J, Uwabo T, Mori Y, Morita M, Nasu Y, Kanazawa S, Toyooka S.

Biopreserv Biobank. 2017 Oct;15(5):484-486. doi: 10.1089/bio.2017.0076. Epub 2017 Sep 14. No abstract available.

PMID:
28910147
38.

PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma.

Otani Y, Ishida J, Kurozumi K, Oka T, Shimizu T, Tomita Y, Hattori Y, Uneda A, Matsumoto Y, Michiue H, Tomida S, Matsubara T, Ichikawa T, Date I.

Sci Rep. 2017 Aug 7;7(1):7391. doi: 10.1038/s41598-017-07745-0.

39.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.

Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.

PMID:
28407039
40.

Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.

Suzawa K, Yamamoto H, Ohashi K, Hashida S, Tomida S, Kubo T, Maki Y, Soh J, Tsukuda K, Kiura K, Miyoshi S, Toyooka S.

Oncol Rep. 2017 May;37(5):3100-3106. doi: 10.3892/or.2017.5567. Epub 2017 Apr 11.

PMID:
28405680
41.

The H3K27 demethylase, Utx, regulates adipogenesis in a differentiation stage-dependent manner.

Ota K, Tong KI, Goto K, Tomida S, Komuro A, Wang Z, Nishio K, Okada H.

PLoS One. 2017 Mar 20;12(3):e0173713. doi: 10.1371/journal.pone.0173713. eCollection 2017. Erratum in: PLoS One. 2017 Apr 19;12 (4):e0176424.

42.

Draft Genome Sequence of Bifidobacterium lemurum DSM 28807T Isolated from the Gastrointestinal Tracts of Ring-Tailed Lemurs (Lemur catta).

Toh H, Matsubara T, Tomida S, Mimura I, Arakawa K, Kikusui T, Morita H.

Genome Announc. 2017 Feb 23;5(8). pii: e01656-16. doi: 10.1128/genomeA.01656-16.

43.

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.

PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017. Erratum in: PLoS One. 2017 Mar 16;12 (3):e0174493.

44.

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.

Sato H, Shien K, Tomida S, Okayasu K, Suzawa K, Hashida S, Torigoe H, Watanabe M, Yamamoto H, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S.

Sci Rep. 2017 Jan 13;7:40847. doi: 10.1038/srep40847.

45.

Comparative genome analyses of Mycobacterium avium reveal genomic features of its subspecies and strains that cause progression of pulmonary disease.

Uchiya KI, Tomida S, Nakagawa T, Asahi S, Nikai T, Ogawa K.

Sci Rep. 2017 Jan 3;7:39750. doi: 10.1038/srep39750.

46.

Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.

Suzawa K, Shien K, Peng H, Sakaguchi M, Watanabe M, Hashida S, Maki Y, Yamamoto H, Tomida S, Soh J, Asano H, Tsukuda K, Nasu Y, Kumon H, Miyoshi S, Toyooka S.

Anticancer Res. 2017 Jan;37(1):301-307.

PMID:
28011506
47.

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.

Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, Hashida S, Miyata-Takata T, Watanabe M, Suzawa K, Soh J, Youyi C, Sato H, Namba K, Torigoe H, Tsukuda K, Yoshino T, Miyoshi S, Toyooka S.

Sci Rep. 2016 Dec 23;6:39557. doi: 10.1038/srep39557.

48.

Draft Genome Sequence of Probiotic Lactobacillus acidophilus Strain L-55 Isolated from a Healthy Human Gut.

Fujii Y, Toh H, Matsubara T, Tomida S, Nguyen CT, Mimura I, Nakamura S, Morita H.

Genome Announc. 2016 Dec 8;4(6). pii: e01357-16. doi: 10.1128/genomeA.01357-16.

49.

The Histone Deacetylase Gene Rpd3 Is Required for Starvation Stress Resistance.

Nakajima E, Shimaji K, Umegawachi T, Tomida S, Yoshida H, Yoshimoto N, Izawa S, Kimura H, Yamaguchi M.

PLoS One. 2016 Dec 1;11(12):e0167554. doi: 10.1371/journal.pone.0167554. eCollection 2016.

50.

MEK inhibitors against MET-amplified non-small cell lung cancer.

Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.

Supplemental Content

Loading ...
Support Center